

Press release
1 June, 2021

Minutes from the Extraordinary General Meeting in Curasight A/S

Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held an extraordinary general meeting on 1 June 2021 at 11:00 (CET). Due to the COVID-19 situation, the extraordinary general meeting will be held as a completely electronic meeting without physical attendance.

The agenda for the general meeting was as follows:

1. Election of Dr. Kirsten Drejer as new member of the board of directors

Dr. Kirsten Drejer was elected as new member of the board of directors. A list of Dr. Kirsten Drejer’s management positions in other companies is enclosed as **appendix 1**.

2. Miscellaneous

There were no matters to be presented.

For more information regarding Curasight A/S, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.

Appendix 1

Dr. Kirsten Drejer's current board directorships and management positions

- 2000 - KD Invest ApS, CEO
- 2017 - Bioneer A/S (www.bioneer.dk), Chairman of the board
- 2017 - Antag Therapeutics ApS (www.antag.com), Chairman of the board
- 2017 - ResoTher Pharma A/S (www.resotherpharma.com), Chairman of the board
- 2018 - Zealand Pharma A/S (www.zealandpharma.com), Board member